• Users Online: 13562
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2021  |  Volume : 4  |  Issue : 3  |  Page : 588-589

Authors' reply to Rajappa


Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India

Date of Submission16-Aug-2021
Date of Acceptance29-Aug-2021
Date of Web Publication08-Oct-2021

Correspondence Address:
Vanita Noronha
Tata Memorial Center, Dr E Borges Road, Parel; Homi Bhabha Natial Institute, Mumbai
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/crst.crst_193_21

Get Permissions


How to cite this article:
Bondili SK, Noronha V. Authors' reply to Rajappa. Cancer Res Stat Treat 2021;4:588-9

How to cite this URL:
Bondili SK, Noronha V. Authors' reply to Rajappa. Cancer Res Stat Treat [serial online] 2021 [cited 2021 Dec 9];4:588-9. Available from: https://www.crstonline.com/text.asp?2021/4/3/588/327782



We thank Dr. Rajappa for showing interest in our article titled “HER2 alterations in non-small cell lung cancer - Druggable or undruggable?”[1],[2] We agree with Dr. Rajappa that there is a lack of clarity on the role of HER2-directed therapy in non-small cell lung cancer (NSCLC). In part this is due to poor understanding of the association between various HER2 alterations, its role in lung oncogenesis, and inconsistent results with HER2-directed agents in the treatment of HER2 altered lung cancers. Although the role of immune checkpoint inhibitors (ICI) is unclear, there are no clear data to not recommend ICI as part of the front-line therapy combinations and we are of opinion that these cases should be treated along the lines of standard therapy as NSCLC without oncogenic driver mutation.[3] We agree that standard chemotherapy should be the first-line treatment of choice and that anti-HER2 therapy should be reserved for the subsequent lines due to the lack of adequate data. If feasible, T-DM1 or trastuzumab deruxtecan should be used in the second line as they have shown efficacy in Phase II studies. Further research is this area is the need of the hour to improve the outcomes of HER2 altered NSCLC.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Rajappa SJ. HER2 alterations in non-small cell lung cancer: More unknowns than knowns! Cancer Res Stat Treat 2021;4:587-8.  Back to cited text no. 1
    
2.
Bondili SK, Nandhana R, Noronha V, Pawar S, Menon N, Shetty O, et al. HER2 alterations in NSCLC-Druggable or nondruggable. Cancer Res Stat Treat 2021;4:374-84.  Back to cited text no. 2
  [Full text]  
3.
Prabhash K, Vora A, Limaye S, Sahoo TP, Batra U, Patil S, et al. Treatment of advanced non-small-cell lung cancer: First line, maintenance, and second line – Indian consensus statement update (Under the Aegis of Lung Cancer Consortium Asia, Indian Cooperative Oncology Network, Indian Society of Medical and Pediatric Oncology, Molecular Oncology Society, and Association of Physicians of India). Cancer Res Stat Treat 2021;4:279-314.  Back to cited text no. 3
  [Full text]  




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed88    
    Printed4    
    Emailed0    
    PDF Downloaded6    
    Comments [Add]    

Recommend this journal